For presentation materials, click here.

The implementation of Basel III in the U.S. and in other jurisdictions may or may not be just around the corner, but it is none too soon for banking organizations to embark on the process of understanding how the evolving regulatory capital regime will affect their balance sheets and operations. One key area of impact will be the treatment of derivatives and related counterparty exposures under the expected new capital rules. Questions - and concerns - abound with respect to areas such as the possible treatment of central counterparty exposures, the treatment of cleared and uncleared OTC exposures, and the availability of credit risk mitigants, to name a few subject areas.

Please join Charles M. Horn and James Schwartz of Morrison & Foerster LLP for a discussion that will include:

• Derivatives under the new regulatory capital rules;
• The state of play under last year’s U.S. regulatory capital proposals;
• Key issues presented by these rule proposals;
• Domestic and international regulatory capital developments; and
• How the final regulatory requirements may play out in light of industry comments.

PLI will provide CLE credit.